Clinical trial · Observational
Responsible Side Effects Management in Oncology
Comprehensive Antineoplastic Therapy Adverse Events Monitoring and Report
NCT04623437CI-TRIAL-00048197R-SEMOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study of pharmacovigilance in oncology. Monitoring and management of AEs during antineoplastic treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Antineoplastic Treatment | — | UNRESOLVED | — |
| Oncology | — | UNRESOLVED | — |
| Pharmacovigilance | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- comparison of perspectives
- timeFrame
- may 2016 until october 2016
- description
- comparison between patient's and oncologist's perspective on severity of AE's during antineoplastic treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: all cancer patients receiving systemic antineoplastic treatment, ECOG 0-2 Exclusion Criteria: age \<18, \>75; other active and severe comorbidities; no solid cancer; IUC patients
References
Publications (0)
Data not yet available
No reference posted for this study.